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Introduction
  Atrial fibrillation (AF) usually occurs in patients with an 
increased vascular risk profile[1]. AF is called idiopathic AF (iAF) 
when meticulous phenotyping does not identify any concomitant 
(cardiovascular) disease. Therefore, these patients are most suitable 
to study early forms of this arrhythmia without the interference of 
associated disease[2].
 In a recent report, Lind et al.[3] used the OlinkProseek Multiplex 
Cardiovascular I kit to identify blood markers associated with 
incident AF in two large-scale population studies. They concluded 
that N-terminal pro-B-type natriuretic peptide (NT-proBNP), 
Fibroblast growth factor 23 (FGF23), Fatty acid-binding protein 4 
(FABP4), growth differentiation factor 15 (GDF-15), and Interleukin 
6 (IL6) are determinants of incident AF, with NT-pro-BNP and 
FGF-23 remaining significant determinants upon correction for 
associated cardiovascular diseases. However, as these individuals were 
recruited from population studies, there were relatively high rates 
of hypertension and of history of stroke, myocardial infarction and 
heart failure.
   In the study reported here, we used the OlinkProseek Multiplex 
Cardiovascular I kit to identify markers associated with the presence 
of AF in otherwise healthy patients, enabling identification of 
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Abstract
Background: Blood biomarkers related to AF could be useful to detect silent AF and to develop stratified strategies for AF prevention. 
Previous studies identified markers that predict incident AF. However, it is difficult to differentiate whether biomarkers relate to underlying 
cardiovascular diseases, are generated by the atria in response to an AF episode, or both. We therefore measured a panel of blood biomarkers 
in patients without overt CVD with and without AF to investigate the association between biomarkers and atrial fibrillation (AF) in patients 
without overt cardiovascular disease (CVD).
Methods: Blood samples – drawn remote from an AF episode – of 60 patients with AF but without overt forms of CVD (idiopathic AF; iAF) 
were compared to 120 matched patients with sinus rhythm only. A novel antibody-based method for quantification of blood biomarkers 
(OlinkProseek Multiplex Cardiovascular) was used to compare 92 biomarkers between the two groups.
Results: N-terminal pro-B-type natriuretic peptide (NT-proBNP), Cathepsin L1, Endothelial cell-specific molecule 1, Cancer Antigen-125 (CA-
125), Heat shock 27kDa protein, Galanin peptides, Proteinase-activated receptor 1, Stem cell factor, and CD40-ligand were all higher in iAF 
patients than in SR controls. Both NT-proBNP (OR1.55(1.07–2.25);p=0.022) and CA-125 (OR1.68(1.07–2.64);p=0.026) were independently 
associated with iAF.
Conclusions: This exploratory study, investigating over 90 cardiovascular blood biomarkers in patients without known CVD, identified one 
established biomarker for paroxysmal AF, NT-proBNP, and a novel marker, CA-125. CA-125 - previously unrelated to paroxysmal AF in an 
otherwise healthy population - may thus be a potential indicator of remote paroxysms of AF.
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markers associated with AF rather than with underlying vascular 
disease.
Material and Methods 
      Of all consecutive patients who underwent cardiac comput-
ed tomography angiography (CTA) in the Maastricht University 
Medical Center between January 2008 and March 2011, all iAF 
patients were selected (n=115), and all age (±1 year), sex and PRO-
CAM cardiovascular risk score-matched(±2%)[4] patients in perma-
nent sinus rhythm (n=275) were selected as described previously[5]. 
All patients underwent CTA to detect subclinical coronary artery 
disease (sCAD). Out of these patients, EDTA-plasma was availa-
ble for analysis in 180 patients (60 iAF, 120 SR). All patients were 
in sinus rhythm during blood sampling, which was performed af-
ter an overnight fast, at the day of CTA. The study was approved 
by the Institutional Review Board, all participants gave written in-
formed consent. The data that support the findings of this study are 
available from the corresponding author upon reasonable request.
    Idiopathic AF was defined as the absence of hypertension 
(antihypertensive drug use, or systolic blood pressure ≥140 mm 
Hg, or diastolic blood pressure ≥90 mm Hg, or left ventricular 
hypertrophy [interventricular septum width >10 mm, posterior wall 
width >10 mm]), diabetes (fasting blood glucose >7.0 mmol/L), or 
hypercholesterolemia (total fasting cholesterol >7.0 mmol/L). In 
addition, none of the patients had a history of coronary artery disease, 
renal dysfunction, chronic heart failure, stroke, malignancy, thyroid 
disease or pulmonary disease, or evidence of structural cardiovascular 
disease on echocardiogram, including valvular heart disease (< grade 
1).
      In all blood samples, the OlinkProseek Multiplex Cardiovascular 
I kit (Olink Proteomics, Uppsala, Sweden) was used to measure 
proteins in EDTA plasma by real timePolymerase Chain Reaction[6]. 
Due to a low call rate (valid measurement in <85% of patients), 
Interleukin 4 (IL4), Natriuretic Peptides B (BNP), and Melusin 
(ITGB1BP2) were not included in further analyses. Values which 
were below the Limit of Detection (LOD) were replaced by the 
LOD value (http://www.olink.com/data-you-can-trust/validation/). 
Ten patients were not included in further analyses based on a large 
number of values below LOD (valid measurement for <85% of the 
proteins). The data from the panels were normalised to the median of 
0 for each protein. This procedure enabled comparisons between the 
measurements from different panels. The panel provides NPX-values 
which allow for relative quantification, values can only be compared 
for the same protein across samples. NPX values for 2 different 
proteins are not comparable.
Statistical analyses
     Statistical analyses were performed using SPSS statistical 
software (IBM SPSS statistics version 23.0, IBM Corporation, 
Armonk, NY). Correlations are presented as Pearson’s r and 
p-value. Normally distributed continuous variables are presented as 
mean±standard deviation, non-normally distributed continuous as 
median[interquartile range], and categorical variables as number of 
patients and percentage. All biomarkers were tested for an association 
with iAF using logistic regression, adjusting for age, sex (following the 
biomarker panel’s instructions) and the presence of CT-angiographic 
sCAD. All significant biomarkers, age, sex and sCAD were included 
in multivariable logistic regression. Results were checked for 
collinearity and interaction among covariates, which were not found. 
Manual backwards elimination, retaining age, sex and sCAD was 
used to construct the final models (retention level set at p<0.10). 
Odds ratios and 95% confidence intervals were calculated. Overall, 
p<0.05 was considered significant. The first author had full access to 
all the data in the study and takes responsibility for its integrity and 
the data analysis.
Results
   As patients originate from a matched case control study, age 
(54.3±9.3 vs 54.1±10.3), sex (30.0% vs 31.7% women) and blood 
pressure (systolic blood pressure 126±9mmHg vs 126±12mmHg, 
diastolic blood pressure 80±10mmHg vs 78±10mmHg) did not differ 
significantly between patients with sinus rhythm and idiopathic AF. 
Echocardiographic parameters did not differ significantly (left atrial 
diameter 37±4mm vs 39±5mm, interventricular septum thickness 
8.8±1.1mm vs 8.6±0.7mm, posterior wall thickness 8.7±1.1mm vs 
8.5±0.6mm, and left ventricular ejection fraction 61[4]% vs 62[5]% 
respectively). The prevalence of sCAD was higher in the iAF group 
(36.5% vs 46.0%), while statin use was comparable (10.6% vs 11.7%). 
Full baseline characteristics and imaging parameters were reported 
earlier[5,7].
         The age, sex and sCAD adjusted odds ratios of the 89 
biomarkers and their 95% confidence interval (95%CI) are shown 
in Supplemental [Table 1]. N-terminal pro-B-type natriuretic 
peptide (NT-proBNP; OR1.70 (1.16–2.49), p=0.006), Cathepsin 
Figure 1:
Shown are age, sex and presence of sCAD-adjusted odds ratios 
and 95% confidence intervals. Panel A: Nine biomarkers differ 
significantly in idiopathic atrial fibrillation (iAF) compared to sinus 
rhythm controls (SR). Panel B: Multivariable regression analysis 
revealed that both NT-proBNP and CA-125 are independently 
associated with the presence of iAF.
For all biomarkers shown p≤0.05.
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L1 (CTSL1; OR3.96 (1.27–12.36, p=0.018), Endothelial cell-
specific molecule 1 (ESM1; OR2.60 (1.15–5.88), p=0.022), Cancer 
Antigen 125 (CA-125; OR 1.93 (1.10–3.38), p=0.022), Heat shock 
27 kDa protein (HSP27; OR1.46 (1.05–2.02), p=0.024), Galanin 
peptides (GAL; OR1.93 (1.07–3.47), p=0.029), Proteinase-activated 
receptor 1 (PAR1; OR2.60 (1.06–6.38), p=0.037), Stem cell factor 
(SCF; OR3.08 (1.06–8.99), p=0.039), and CD40 ligand (CD40L; 
OR1.43 (1.00–2.06), p=0.050) were all higher in iAF patients than 
in SR controls [Figure 1]. The mean expression of these 9 biomarkers 
is shown in [Figure 2]. There were no significant differences in the 
levels of the other biomarkers between iAF and controls.
Table 1:
Odds ratios, corrected for age, sex and subclinical coronary artery 
disease (sCAD) on computed tomography, of 89 biomarkers of the 
idiopathic AF versus the sinus rhythm control group. Shown are 
OR(95% CI) and corresponding p-value
Age, sex and sCAD 
adjusted
OR (95% CI) P
N-terminal pro-B-type natriuretic peptide (NT-proBNP) 1.701 (1.163 – 2.488) 0.006
Cathepsin L1 (CTSL1) 3.961 (1.269 – 
12.356)
0.018
Endothelial cell-specific molecule 1 (ESM1) 2.601 (1.151 – 5.876) 0.022
Cancer Antigen 125 (CA125) 1.927 (1.101 – 3.375) 0.022
Heat shock 27 kDa protein (HSP27) 1.459 (1.052 – 2.023) 0.024
Galanin peptides (GAL) 1.925 (1.068 – 3.468) 0.029
Proteinase-activated receptor 1 (PAR1) 2.601 (1.060 – 6.384) 0.037
Stem cell factor (SCF) 3.082 (1.057 – 8.986) 0.039
CD40 ligand (CD40L) 1.433 (1.000 – 2.055) 0.050
TNF-related apoptosis-inducing ligand (TRAIL) 3.048 (0.952 – 9.759) 0.061
Platelet endothelial cell adhesion molecule (PECAM1) 2.022 (0.943 – 4.334) 0.070
Pentraxin-related protein PTX3 (PTX3) 1.774 (0.933 – 3.375) 0.081
Monocyte chemotactic protein 1 (MCP1) 0.525 (0.248 – 1.113) 0.093
C-X-C motif chemokine 1 (CXCL1) 1.387 (0.945 – 2.035) 0.095
Spondin 1 (SPON1) 2.249 (0.840 – 6.026) 0.107
Tissue factor (TF) 2.385 (0.809 – 7.029) 0.115
Beta-nerve growth factor (Beta-NGF) 1.972 (0.839 – 4.637) 0.120
Pappalysin-1 (PAPPA) 1.673 (0.853 – 3.284) 0.134
TNF-related activation-induced cytokine (TRANCE) 1.531 (0.865 – 2.710) 0.143
E-selectin (SELE) 0.649 (0.360 – 1.171) 0.151
Leptin (LEP) 0.740 (0.483 – 1.134) 0.167
Interleukin-6 receptor subunit alpha (IL6RA) 1.766 (0.762 – 4.091) 0.185
Fractalkine (CX3CL1) 1.836 (0.740 – 4.559) 0.190
Matrix metalloproteinase 12 (MMP12) 1.371 (0.842 – 2.230) 0.204
Proto-oncogene tyrosine-protein kinase
Src (SRC)
1.332 (0.847 – 2.097) 0.215
Follistatin (FS) 1.502 (0.789 – 2.861) 0.216
Agouti-related protein (AGRP) 1.493 (0.773 – 2.885) 0.233
Epidermal growth factor (EGF) 1.207 (0.879 – 1.658) 0.245
Fibroblast growth factor 23 (FGF23) 1.301 (0.833 – 2.030) 0.247
Myoglobin (MB) 0.708 (0.390 – 1.285) 0.256
Adrenomedullin (AM) 1.660 (0.685 – 4.021) 0.261
Interleukin 16 (IL16) 1.457 (0.747 – 2.841) 0.269
Heparin-binding EGF-like growth factor (HB-EGF) 1.637 (0.668 – 4.010) 0.281
Osteoprotegerin (OPG) 1.572 (0.650 – 3.799) 0.315
Dickkopf-related protein 1 (DKK1) 1.313 (0.764 – 2.257) 0.325
Myeloperoxidase (MPO) 1.723 (0.578 – 5.133) 0.329
NF-kappa-B essential modulator (NEMO) 1.234 (0.800 – 1.905) 0.342
Matrix metalloproteinase 3 (MMP3) 1.308 (0.751 – 2.278) 0.344
ST2 protein (ST2) 1.336 (0.729 – 2.450) 0.348
Interleukin-27 subunit alpha (IL27A) 1.641 (0.573 – 4.697) 0.356
TNF-related apoptosis-inducing ligand receptor 2 
(TRAILR2)
0.615 (0.215 – 1.759) 0.365
P-selectin glycoprotein ligand 1 (PSGL-1) 0.455 (0.082 – 2.528) 0.368
CD40L receptor (CD40) 1.403 (0.670 – 2.939) 0.369
Placenta growth factor (PIGF) 1.529 (0.566 – 4.130) 0.402
Membrane-bound aminopeptidase P (mAmP) 0.877 (0.643 – 1.198) 0.410
Continue the table .. .. ...
Tumor necrosis factor receptor 2 (TNFR2) 1.352 (0.619 – 2.954) 0.450
Thrombomodulin (TM) 1.467 (0.520 – 4.135) 0.469
Interleukin 8 (IL8) 0.794 (0.422 – 1.495) 0.475
Macrophage colony stimulating factor (CSF1) 1.650 (0.408 – 6.673) 0.482
Tumor necrosis factor ligand superfamily member 14 
(TNFSF14)
1.353 (0.562 – 3.257) 0.501
Receptor for advanced glycosylation end products (RAGE) 1.298 (0.549 – 3.071) 0.552
Growth/differentiation factor 15 (GDF-15) 1.212 (0.607 – 2.419) 0.586
T-cell immunoglobulin and mucin domain 1 (TIM) 0.873 (0.530 – 1.437) 0.592
Angiopoietin-1 receptor (TIE2) 1.287 (0.421 – 3.935) 0.658
Interleukin 6 (IL6) 0.922 (0.632 – 1.343) 0.672
Tissue-type plasminogen activator (tPA) 1.150 (0.593 – 2.233) 0.679
Matrix metalloproteinase 1 (MMP1) 0.902 (0.544 – 1.496) 0.689
Hepatocyte growth factor (HGF) 1.154 (0.565 – 2.356) 0.694
Eosinophil cationic protein (ECP) 1.112 (0.644 – 1.919) 0.703
C-C motif chemokine 4 (CCL4) 1.106 (0.656 – 1.863) 0.706
Vascular endothelial growth factor D (VEGF-D) 0.901 (0.505 – 1.606) 0.723
Prolactin (PRL) 1.089 (0.678 – 1.747) 0.725
SIR2-like protiein (SIRT2) 1.038 (0.821 – 1.038) 0.757
C-X-C motif chemokine 6 (CXCL6) 0.935 (0.587 – 1.489) 0.776
Chitinase-3-like protein 1 (CHI3L1) 0.939 (0.602 – 1.463) 0.780
Interleukin 1 receptor antagonist protein (IL1RA) 0.924 (0.519 – 1.654) 0.789
Galectin 3 (GAL3) 0.915 (0.463 – 1.810) 0.799
Tumor necrosis factor receptor superfamily member 6 
(FAS)
1.123 (0.445 – 2.835) 0.806
Urokinase plasminogen activator surface receptor (UPAR) 1.119 (0.451 – 2.773) 0.808
Cathepsin D (CTSD) 0.914 (0.436 – 1.915) 0.811
Kallikrein 11 (hK11) 0.904 (0.390 – 2.093) 0.814
Kallikrein 6 (KLK6) 1.097 (0.452 – 2.662) 0.837
Vascular endothelial growth factor A (VEGF-A) 1.095 (0.400 – 3.000) 0.859
Cystatin B (CSTB) 1.045 (0.641 – 1.703) 0.860
Fatty acid-binding protein 4 (FABP4) 1.066 (0.521 – 2.183) 0.861
Lectin-like oxidized LDL receptor 1 (LOX1) 1.043 (0.605 – 1.798) 0.879
C-C motif chemokine 20 (CCL20) 0.978 (0.709 – 1.349) 0.890
Caspase 8 (CASP8) 1.032 (0.639 – 1.668) 0.897
Resistin (RETN) 0.962 (0.519 – 1.781) 0.901
Platelet-derived growth factor subunit B (PDGFsuB) 1.015 (0.773 – 1.334) 0.912
Protein S100-A12 (EN-RAGE) 0.969 (0.553 – 1.700) 0.913
Interleukin 18 (IL18) 1.034 (0.530 – 2.018) 0.921
Growth hormone (GH) 0.992 (0.844 – 1.166) 0.924
Matrix metalloproteinase (MMP10) 1.027 (0.583 – 1.809) 0.927
C-C motif chemokine 3 (CCL3) 1.044 (0.408 – 2.670) 0.928
Tumor necrosis factor receptor 1 (TNFR1) 1.043 (0.373 – 2.918) 0.937
Renin (REN) 1.004 (0.622 – 1.618) 0.988
C-X-C motif chemokine 16 (CXCL16) 0.993 (0.338 – 2.923) 0.990
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still to be determined[10]. CA-125 has before been linked – in 
small studies – to new-onset AF in patients with recompensated 
acute heart failure[11] as well as in post-menopausal women[12], but 
not yet to prevalent AF in a healthy population. There may be 
three possible explanations for the association between CA-125 
and AF. Firstly, as CA-125 positively correlates with TNF-α, IL-
6, IL-10[13] and IL-1β[14], it may be hypothesized to be a marker 
of the presence of underlying low-grade inflammation in this 
study population. Secondly: CA-125 is produced in response to 
mechanical stress or inflammation by different tissues derived from 
coelomic epithelium, such as the pericardium and pleura[10]. Based on 
the strong anatomical relation between the posterior left atrium and 
the pericardium[15] and the dominance of pulmonary vein triggers in 
early AF, the rise in CA-125 may be hypothesized to be a reflection 
of the interplay between atrium and pericardium. Lastly, as CA-125 
is shown to correlate with pleural effusion[16], it may be hypothesized 
that the paroxysms of AF have led to – transient – pleural effusion 
with an associated rise in CA-125.Univariable regression analysis 
revealed that several pathophysiological processes may be active in 
patients with early forms of AF, such as angiogenesis (CTSL1[17], 
ESM1[18]), endothelial dysfunction (ESM1[18], SCF[19]), cellular stress 
(HSP27[20]), cardiac remodelling (CTSL1[20]), cardiac remodelling 
(CTSL1[21]) and activation of the coagulation system (GAL[22], 
PAR1[23], and CD40L[24]). The markers of a hypercoagulable state are 
in line withprevious reports of a prothrombotic state veryearly in the 
pathogenesis of AF[25,26]. Clearly, a much larger patient sample would 
be needed to verify any of these interactions which did not uphold 
during multivariable testing.
        Multivariable analysis showed that both CA-125 and NT-
proBNP, adjusted for age, sex and sCAD, are associated with a 
Figure 2:
Unadjusted box-plots of 9 biomarkers that were found to 
be significantly different between patients without overt 
cardiovascular disease, with and without atrial fibrillation. Shown 
are mean and standard deviations. 
** indicates p<0.01, * indicates p<0.05.
CA-125=Cancer Antigen 125; CD40L=CD40 ligand; CTSL1=Cathepsin L1 ; ESM1=Endothelial 
cell□specific molecule 1; GAL=Galanin peptides; HSP27=Heat shock 27 kDa protein; iAF=idiopathic 
atrial fibrillation, NPX=normalized protein expression, NT-proBNP=N□terminal pro□B□type 
natriuretic peptide; PAR1=Proteinase-activated receptor 1; SCF=Stem cell factor; SR=sinus rhythm.
history of iAF (OR for CA-125 2.25 (1.27-3.99), p=0.005 and NT-
proBNP 1.79 (1.22-2.62), p=0.002). NT-proBNP and CA-125 do 
not correlate with each other (r=-0.09, p=0.27). [Figure 3] shows 
the prevalence of iAF in tertiles of the CA-125 (21.7%, 28.6% and 
35.0%; p=0.27) and NT-proBNP levels (19.3%, 26.2% and 39.7%; 
p=0.04). The highest prevalence of iAF can be found in patients 
with levels of both CA-125 and NT-proBNP in the highest tertile 
(50.0%), with an intermediate prevalence in patients with either CA-
125 (30.0%) or NT-proBNP (37.2%) in the highest tertile and the 
lowest prevalence in patients with none of the markers in the highest 
tertile (18.9%; p=0.005).
Discussion
  From this study, it can be concluded that even in a healthy 
population without cardiovascular disease, the levels of NT-proBNP 
and CA-125 are associated with AF. Results from this study 
furthermore show that the levels of CTSL1, ESM1, HSP27, GAL, 
PAR1, SCF and CD40L may contain additional information on the 
presence of a history of AF.
Multivariable analysis showed that two markers are independently 
associated with the presence of a history of AF: NT-proBNP and 
CA-125. NT-proBNP has been recognized as a marker of incident 
AF in population studies, on top of risk scores based on the presence 
of cardiovascular disease[8,9]. The data from this cohort confirm that 
elevated NT-proBNP blood levels are a marker of (remote) episodes 
of paroxysmal AF even in the absence of concomitant vascular disease.
 CA-125 is in current clinical use in the follow-up of ovarian 
cancer, but the value of CA-125 as a biomarker in cardiology is 
Figure 3:
Percentages of patients with idiopathic atrial fibrillation (iAF) in 
tertiles of CA-125 and NT-proBNP levels. SR=Sinus Rhythm
* indicates P<0.05, ** indicates P<0.01.natriuretic peptide; PAR1=Proteinase-activated receptor 1; 
SCF=Stem cell factor; SR=sinus rhythm.
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cardiovascular disease.
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Conclusion 
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